Edition:
United Kingdom

Fagron NV (FAGRO.BR)

FAGRO.BR on Brussels Stock Exchange

14.93EUR
14 Dec 2018
Change (% chg)

€-0.39 (-2.55%)
Prev Close
€15.32
Open
€15.19
Day's High
€15.23
Day's Low
€14.88
Volume
62,536
Avg. Vol
146,989
52-wk High
€17.10
52-wk Low
€10.02

Latest Key Developments (Source: Significant Developments)

Fagron NV H1 Net Profit EUR 18.8 Million
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Fagron NV ::REALISED ORGANIC TURNOVER GROWTH OF 8.5%.Q2 REBITDA INCREASED BY 1.1% (+6.9% AT CONSTANT EXCHANGE RATES) TO € 48.7 MILLION.SAYS Q2 RECURRENT NET PROFIT INCREASED BY 6.6% TO EUR 22.3 MILLION.H1 NET PROFIT EUR 18.8 MILLION VERSUS EUR 21.1 MILLION YEAR AGO.Q2 OPERATIONAL CASH FLOW OF € 34.4 MILLION.Q2 NET FINANCIAL DEBT/REBITDA RATIO OF 2.72."WE EXPECT THAT WE CAN CONTINUE POSITIVE TREND OF FIRST SEMESTER IN SECOND SEMESTER OF 2018".  Full Article

Nuvo Pharmaceuticals(Ireland)Limited Enters Into Resultz License And Supply Agreement With Fagron Belgium NV
Monday, 23 Jul 2018 

July 23 (Reuters) - Nuvo Pharmaceuticals Inc ::NUVO PHARMACEUTICALS(IRELAND) LIMITED ENTERS INTO RESULTZ LICENSE AND SUPPLY AGREEMENT WITH FAGRON BELGIUM NV FOR BELGIUM, THE NETHERLANDS AND LUXEMBOURG.NUVO PHARMACEUTICALS - NUVO IRELAND WILL BEGIN TO EARN ROYALTY REVENUE UNDER DEAL WITH FAGRON.NUVO PHARMACEUTICALS - TAKEDA HAS RETURNED ITS PRODUCT RIGHTS TO CO ,FAGRON TO RELAUNCH RESULTZ IN BELGIUM, NETHERLANDS, LUXEMBOURG.  Full Article

Fagron Reports Q1 Turnover At 109.1 Million Euros
Thursday, 12 Apr 2018 

April 12 (Reuters) - Fagron NV ::Q1 TURNOVER EUR 109.1 MILLION VERSUS EUR 109.0 MILLION YEAR AGO.FURTHER GROWTH IN TURNOVER AND PROFITABILITY EXPECTED IN 2018.SEES TURNOVER DEVELOPMENT TO NO LONGER BE NEGATIVELY AFFECTED IN THE CURRENT QUARTER.  Full Article

Cannimed Therapeutics Announces Cannabis Distribution Agreement With Fagron NV
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Cannimed Therapeutics Inc ::CANNIMED THERAPEUTICS INC. ANNOUNCES STRATEGIC INTERNATIONAL CANNABIS DISTRIBUTION AGREEMENT WITH FAGRON NV.CANNIMED THERAPEUTICS INC - ‍ IS WORKING TO SUPPLEMENT ITS CANADIAN GMP COMPLIANT STATUS WITH GMP CERTIFICATION IN EUROPE FOR ITS CANNABIS PRODUCTS.CANNIMED THERAPEUTICS INC - ‍FAGRON AND CANNIMED ANTICIPATE FIRST PRODUCT SALES INTO GERMANY WILL COMMENCE IN Q3 2018​.CANNIMED THERAPEUTICS INC - ‍ PRIMARY INITIAL FOCUS OF CANNABIS DISTRIBUTION AGREEMENT WITH FAGRON NV​ ON GERMANY.CANNIMED THERAPEUTICS- ‍FAGRON TO UTILIZE ITS DISTRIBUTION NETWORK TO MARKET, DISTRIBUTE CANNIMED MEDICINAL CANNABIS PRODUCTS TO 17 SPECIFIED COUNTRIES​.  Full Article

Fagron appoints ‍Rafael Padilla to succeed Hans Stols as CEO
Monday, 27 Nov 2017 

Nov 27 (Reuters) - FAGRON NV ::‍RAFAEL PADILLA SUCCEEDS HANS STOLS AS CEO​.‍MR. STOLS WILL RESIGN FROM ALL HIS FUNCTIONS AND MANDATES WITH IMMEDIATE EFFECT​.  Full Article

Fagron Q3 turnover ‍​up at 103.6 million euros
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - FAGRON NV ::Q3 TURNOVER EUR ‍​103.6 MILLION VERSUS EUR 103.4 MILLION YEAR AGO.BACKLOG IS EXPECTED TO BE LARGELY CLEARED IN THE Q1 OF 2018‍​.  Full Article

Fagron acquires All Chemistry in Brazil
Thursday, 5 Oct 2017 

Oct 5 (Reuters) - FAGRON NV ::FAGRON FURTHER EXECUTES BUY-AND-BUILD STRATEGY WITH ACQUISITION OF ALL CHEMISTRY IN BRAZIL.  Full Article